This article looks at what a transition to propellants with lower Global Warming Potential will involve and the lessons that can be learned from the industry’s earlier transition from CFCs to HFAs. Key issues that need to be addressed as formulators learn to work with propellants such as HFA 152a and HFO 1234ze include solubility of the active, the profile of the emitted spray, droplet size and evaporation, and electrostatic characteristics.
Aptar Pharma offers a comprehensive suite of services for those looking to accelerate their transition to low carbon MDIs including the Nanopharm SmartTrack™ platform which provides a wealth of information for formulation optimization.
Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery
This Might Also Be of Interest
Aptar Pharma expert Q&A on digital health and connected drug delivery
Publications, Pharmaceutical, Brand Differentiation, Product Solutions, Innovation & Insights, Device Innovations
Aptar Pharma discusses Article 117 of the Medical Device Regulations
Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights
Drug Delivery Systems & Services for Lifecycle Management of Crisis Medications ...
Webinars, Pharmaceutical, Brand Differentiation, Product Solutions, Innovation & Insights, Device Innovations
Using in vitro dissolution tests for local bioequivalence in OINDPs
Webinars, Pharmaceutical, Innovation & Insights, Market Insights
